Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
NPJ Vaccines|December 18, 2020
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidateRamon Roozendaal, Jenny Hendriks, Thierry van Effelterre, et al.
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.
The New England Journal of Medicine|April 21, 2021
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19Jerald Sadoff, Glenda Gray, An Vandebosch, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
The New England Journal of Medicine|February 9, 2022
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Glenda Gray, An Vandebosch, et al.
Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Vaccine|June 29, 2023
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trialsChristine B Turley, LaKesha Tables, Trevon Fuller, et al.
Research Square|July 3, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig Magaret, Li Li, Allan deCamp, et al.
Nature Communications|March 12, 2024
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig A Magaret, Li Li, Allan C deCamp, et al.
Nature Communications|November 12, 2024
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trialLindsay N Carpp, Ollivier Hyrien, Youyi Fong, et al.
Pageof 4